Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease

Recruiting Phase 4 Interventional Study
Graves Disease Relapse Treatment Drug Withdrawal
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 65
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
240 (estimated)
Sponsor
The First Affiliated Hospital with Nanjing Medical University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
In this study, the dose of methimazole was adjusted according to the different states of thyroid function, and the effects of conventional therapy and intensive therapy on the cumulative recurrence of Graves' hyperthyroidism after two years of drug withdrawal were evaluated. At the same time, the changes of immune indexes and inflammatory factors in the regulation process were evaluated. This stud…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Graves hyperthyroidism (responsible for doctors' clinical diagnosis) * Age 18-65, for both men and women * Thyroid receptor antibody (TRAb) was positive * Take part in this research voluntarily and sign the informed consent form Exclusion Criteria: * Those who have used gluc…
Contacts

Xuqin Zheng

13912902902

zhengxuqin@njmu.edu.cn

CONTACT